
-
BioVie NasdaqCM:BIVI BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Location: 680 West Nye Lane, Carson City, NV, 89703, United States | Website: https://bioviepharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-2.804M
Cash
24.41M
Avg Qtr Burn
-5.506M
Short % of Float
6.64%
Insider Ownership
13.09%
Institutional Own.
5.98%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BIV201 Details Ascites | Phase 3 Initiation | |
NE3107 Details Alzheimer's disease | Phase 3 Initiation | |
Bezisterim (NE3107) Details Early Parkinson's disease | Phase 2b Data readout |